the aid library

LIST OPTIONS

Filter

1499

Download (134)

View PDF (186)

Nota Informativa da OMS COVID-19: Considerações sobre cuidados com a tuberculose (TB)

OMS (WHO) OPAS, OMS (2021) CC

WHO Information Leaflet COVID-19: Considerations on tuberculosis (TB) care

Download (100)

View PDF (152)

Imunidade natural contra a COVID-19 Informe científico 10 de maio de 2021

Organização Mundial da Saúde (OMS) OPAS, OMS (2021) C_WHO

Natural immunity against COVID-19 Scientific report 10 May 2021

Download (92)

View PDF (144)

Key considerations: Indigenous Peoples in COVID-19 response and recovery

Social Science in Humanitarian Action Platform (2021) C2

English Analysis on Brazil about Health, Protection and Human Rights and Epidemic; published on 26 May 2021 by SSHAP

Download (86)

View PDF (114)

ACTUALIZACIÓN COVID-19

Ferres M., Potin M. (2020) C2

El presente material es un aporte NO OFICIAL y volutario realizado a partir de la reunión clínica del equipo de Infectología Pediátrica PUC. Su objetivo de aportar con un recurso educativo que contribuya a la actualización de los profesionales y estudiantes de la salud respecto a este problem... more

Download (200)

View PDF (155)

Lineamientos para el abordaje de la TB ante el COVID-19

Ministerio de Salud, Bogota, Colombia (2020) CC

Download (164)

View PDF (199)

The COVID-19 HEalth caRe wOrkErs Study (HEROES): Regional Report from the Americas

Pan American Health Organisation PAHO (2022) C_WHO

The COVID-19 HEalth caRe wOrkErs Study (HEROES): Regional Report from the Americas is a multicenter prospective cohort study to assess the impact of the COVID-19 pandemic on the mental health of health care workers in 26 countries on four continents and how it is affected by several factors at diffe... more

Download (94)

View PDF (140)

Puntos clave sobre la COVID-19 en los servicios de urgencias: propuestas de mejora para su atención en Latinoamérica

Julián-Jiménez, A.; et al. (2021) CC

Emergencias 2021: 33: 42-58

External Link

COVID-19 Results Briefing Peru

Institute for Health Metrics and Evaluation (2022) CC

This document contains summary information on the latest projections from the IHME model on COVID-19 in Peru. The model was run on July 15, 2022, with data through July 10, 2022.

Download (89)

View PDF (148)

The sociodemographic impacts of the COVID-19 pandemic in Latin America and the Caribbean

United Nations ECLAC (2022) C1

Latin America and the Caribbean is characterized by a matrix of social inequality whose axes —such as socioeconomic stratum, gender, stage in the life cycle, ethnicity and race, territory, disability, and immigration status— create multiple, often concurrent, situations of exclusion and discri... more

External Link

The Lancet Commission on lessons for the future from the COVID-19 pandemic

Sachs, J., Karim, S., Aknin, L. et al. The Lancet Commissions (2022) CC

This Commission report aims to contribute to a new era of multilateral cooperation based on strong UN institutions to reduce the dangers of COVID-19, forestall the next pandemic, and enable the world to achieve the agreed goals of sustainable development, human rights, and peace that governments are... more

Download (163)

View PDF (178)

A clinical case definition for post Covid-19 condition in children and adolescents by expert consensus

World Health Organisation (WHO) (2023) C_WHO

Background: The World Health Organization (WHO) published a clinical case definition of post COVID-19 condition, by a Delphi consensus, on 6 October 2021. That process concluded that a separate definition may be applicable for children. It is important to understand the frequency, characteristics ... more

Download (162)

View PDF (179)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171 countries across all six WHO Regions and was rapidly re... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (100)

View PDF (124)

Sentinel surveillance programme for hospitalised individuals with COVID-19 in South Africa

Jassat, W.; et al. (2020) CC